trimethoprim tablet
carilion materials management - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the
trimethoprim viatris trimethoprim 300 mg tablet blister pack
alphapharm pty ltd - trimethoprim, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate; purified talc; magnesium stearate - this product approved for registration as a variation of a product accepted for inclusion in the artg as 'currently supplied' at the commencement of the act. indications are held in artg paper records. previous product number aust r 17577 and 43120. product information not reviewed. indications as at 5 december 1984 : treatment of acute urinary tract infections caused by sensitive organisms.
trimethoprim tablet
novitium pharma llc - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the results of
trimethoprim tablet
avpak - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg
trimethoprim tablet
golden state medical supply, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacter
trimethoprim 200mg tablets
milpharm limited - trimethoprim - tablets - 200mg - systemic antibacterial - treatment of susceptible infections caused by trimethoprim sensitive organisms including most gram-positive and gram-negative aerobic organisms, including haemophilus influenzae, streptococcus pneumoniae, klebsiella pneumonia, staphylococcus aureus, eschersichia coli, enterobacter, proteus and streptococcus faecalis. exceptions include anaerobic bacteria. mycobacterium tuberculosis, neisseria gonorrhoeae, pseudomonas aeruginosa and treponema pallidum. prophylaxis of recurrent urinary tract infections. consideration should be given to official guidance on the appropriate use of antibacterial agents
trimethoprim 100mg tablets
milpharm limited - trimethoprim - tablets - 100mg - treatment of susceptible infections caused by trimethoprim sensitive organisms including most gram-positive and gram-negative aerobic organisms, including haemophilus influenzae, streptococcus pneumoniae, klebsiella pneumonia, staphylococcus aureus, eschersichia coli, enterobacter, proteus and streptococcus faecalis. exceptions include anaerobic bacteria. mycobacterium tuberculosis, neisseria gonorrhoeae, pseudomonas aeruginosa and treponema pallidum. prophylaxis of recurrent urinary tract infections. consideration should be given to official guidance on the appropriate use of antibacterial agents
sulfamethoxazole and trimethoprim tablet
redpharm drug, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - trimethoprim 160 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute oti
trimethoprim tablet
actavis pharma, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg
sulfamethoxazole and trimethoprim tablet
redpharm drug, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - trimethoprim 160 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis m